The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2021. Without the cooperation between ImmunoLogik and the university hospital Erlangen for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS, the identification of IML-206 against SARS-CoV-2 could have never been made. Only with the right scientific partners, infrastructure with laboratories of the biosafety level 2 and 3…
Focused on the research, development and marketing of active substances and therapies for the treatment of congenital and acquired diseases of the immune system. Developing the unique innovative drug candidate IML-106 for the treatment of HIV patients who would otherwise inevitably die sooner or later due to the outbreak of AIDS. Target customers are pharmaceutical companies as development and licensing partners looking to expand their portfolio of HIV medicines.
Milestones since Aescuvest Investment
Grant of US and EU patents for IML-106. Successful development and testing of a new solubiliser for IML-106. Development of new drug candidate IML-206 against SARS-CoV-2. Development of an unexpected revenue stream under a licensing agreement.
ImmunoLogik has developed an innovative lead candidate for the efficient and vital treatment of HIV patients who have already explored all other modern therapies.
Lars Siegert, Dr. Christian Setz
Round at time of investment